Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
The evolving role of BTK inhibitors in CLL
May 1, 2026
25m 04s
Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians
Apr 24, 2026
19m 10s
The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care
Apr 16, 2026
13m 43s
Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies
Apr 9, 2026
21m 43s
Myeloid Monthly: breaking news & updates from the classification advancement meeting
Apr 2, 2026
35m 55s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/1/26 |  The evolving role of BTK inhibitors in CLL | No description provided. | 25m 04s | ||||||
| 4/24/26 | Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians | In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the main factors contributing to the observed reduction in the incidence of higher-grade CRS and ICANS following CAR-T. Following this, Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, shares insight into infection prevention and antibiotic use in febrile patients, and Birte Friedrichs, MD, Düsseldorf University Hospital, Düsseldorf, Germany, discusses the misconception among physicians that the side effects of CAR-T are too severe for their patients, noting the potential impact of this belief. You will then hear from Megan Melody, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, who shares advice for community physicians monitoring patients for less common toxicities following CAR-T, and Kenneth Lim, MBBS, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, who highlights AEs that physicians should be aware of when treating patients with multiple myeloma with ciltacabtagene autoleucel (cilta-cel). | 19m 10s | ||||||
| 4/16/26 | The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care | This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors. Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of frontline treatment in achieving long-term disease control. You will also hear from David Lewis, MBChB, PhD, FRCPath, Plymouth University, Plymouth, UK, Tycel Phillips, MD, City of Hope, Duarte, CA, and Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, who share perspectives on patient selection for therapy, biological risk factors, and how treatment decisions differ between academic and community settings. | 13m 43s | ||||||
| 4/9/26 | Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies | This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents.Experts discuss the growing importance of donor germline genetics, updated guidance for Hodgkin lymphoma transplantation, the shifting role of CAR T‑cell therapy in non‑Hodgkin lymphoma, and how measurable residual disease (MRD) is shaping transplant decisions and post‑transplant care.Overall, the episode highlights how these developments are improving personalization and outcomes in haemopoietic stem cell transplantation. | 21m 43s | ||||||
| 4/2/26 | Myeloid Monthly: breaking news & updates from the classification advancement meeting | This VJHemOnc podcast introduces the first edition of Myeloid Monthly, focusing on key developments in myeloid malignancies. Amer Zeidan, MD, Yale University, New Haven, CT, is joined by Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Sanam Loghavi, MD, MD Anderson Cancer Center, Houston, TX, to discuss breaking updates from the Classification Advancement Meeting (CAM), held in Chicago in March 2026. The panel explores the evolving classification of myeloid neoplasms, including the shift from morphology to molecular genetics, key differences between the WHO and ICC systems, and areas of ongoing debate such as MDS, AML, and overlap syndromes. They also discuss the process of harmonising these frameworks, the clinical implications for diagnosis, trial design, and patient care, and how CAM recommendations are expected to inform a future unified WHO classification. | 35m 55s | ||||||
| 3/27/26 | How AI is transforming hematologic oncology | This VJHemOnc podcast explores how artificial intelligence (AI) is transforming hematologic oncology, from clinical research and diagnostics to risk prediction and therapy development. Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses AI-driven approaches to improving clinical trial enrollment, while Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, highlights advances in AI-based pathology for lymphoma classification. Ciara Freeman, MD, PhD, Moffitt Cancer Center, Tampa, FL, examines multimodal AI for predicting CAR T-cell outcomes, while Zinaida Good, PhD, Stanford University, Stanford, CA, and Andrea Schmidts, MD, Technical University of Munich, Munich, Germany, explore AI applications in CAR T-cell design. Gianluca Asti, MSc, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy, discusses federated learning for data sharing, and Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, highlights challenges in real-world AI implementation. | 20m 22s | ||||||
| 3/20/26 | MRD in ALL and AML: from prognostic marker to clinical endpoint | This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the potential of MRD as a surrogate endpoint in AML, while Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, presents supporting evidence from large registry analyses. Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, highlights the integration of MRD into risk stratification, while Wendy Stock, MD, University of Chicago Medical Center, Chicago, IL, reviews MRD detection methods, emerging technologies, and practical implementation in ALL. | 21m 21s | ||||||
| 2/27/26 | Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026 | Nurses play a key role in the CAR T-cell therapy process. In this podcast episode, you will hear insights into nursing in CAR-T and cellular therapy through exclusive interviews from the recent EBMT-EHA 8th European CAR T-cell Meeting. First, Erik Aerts, RN, University of Zurich, Zurich, Switzerland, will walk through the CAR T-cell process from a nursing perspective, and Mairéad Ní Chonghaile, RGN, BNS, MSc, St James’s Hospital, Dublin, Ireland, will emphasize the importance of a true collaborative approach to care in the CAR-T process and discuss how to appropriately address fears or misconceptions patients may have. You will then hear from Thomas Jezequel, MSc, Nantes University Hospital, Nantes, France, who will comment on the role of social media in a patient’s CAR T-cell therapy journey and share messages for young nurses in the cellular therapy space. Finally, Jemma Stewart, nurse educator, and Ella Weisser, clinical nurse specialist, Peter MacCallum Cancer Centre, Melbourne, Australia, will provide insight into the recommended frequency of Immune Effector Cell-Associated Encephalopathy (ICE) assessment in patients receiving CAR-T. | 17m 59s | ||||||
| 2/20/26 | Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes | Today’s episode of the VJHemOnc podcast features updates from a number of clinical trials exploring BTK inhibitors (BTKi) and BTKi-containing regimens in non-Hodgkin lymphoma (NHL) that were presented at the 2025 ASH Annual Meeting. First, you will hear updates in mantle cell lymphoma (MCL) trials from Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Austin Kim, MD, Dana-Farber Cancer Institute, Boston, MA, and Tycel Phillips, MD, City of Hope, Duarte, CA. Following this, Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, share BTKi trial updates in Waldenström’s macroglobulinemia (WM). Finally, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the preliminary results of the MITHIC-FL2 trial (NCT05389293) investigating mosunetuzumab plus zanubrutinib in newly diagnosed high-burden follicular lymphoma (FL), and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the primary analysis of the Smart Stop trial (NCT04978584), which evaluated a four-drug combination in newly diagnosed diffuse large B-cell lymphoma (DLBCL). | 26m 09s | ||||||
| 2/6/26 | ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD | This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025, spanning risk stratification, optimisation of frontline therapy, emerging immunotherapies, and MRD assessment. Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses a newly validated staging system defining ultra-high-risk AL amyloidosis in the era of daratumumab-based therapy. Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents Phase II AQUARIUS trial (NCT05250973) data evaluating daratumumab-VCd dosing in newly diagnosed disease and shares Phase I trail (NCT06158854) results of the BCMA x CD3 bispecific antibody etentamig in relapsed or refractory AL amyloidosis. Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviews early results from the NEXICART-2 trial (NCT06097832) of the BCMA-directed CAR T-cell therapy NXC-201. Andrew Staron, MD, Boston Medical Center, Boston, MA, discusses the prognostic significance of sustained MRD negativity, while Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, presents real-world data on BCMA-directed CAR T-cell and bispecific therapies in systemic AL amyloidosis. | 28m 49s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 1/30/26 | Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies | This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025, spanning frontline therapy, molecularly targeted approaches, venetoclax-based combinations, and emerging immunotherapies. Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the Phase II PARADIGM study (NCT04801797) comparing azacitidine plus venetoclax with intensive chemotherapy, alongside updated KOMET-007 trial (NCT05735184) results of ziftomenib plus azacitidine and venetoclax in NPM1-mutated or KMT2A-rearranged AML. Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the Phase I/II VICEROY study (NCT05520567) of venetoclax, azacitidine, and gilteritinib in newly diagnosed FLT3-mutated AML ineligible for intensive therapy. Naval Daver, MD, MD Anderson Cancer Center, Houston, TX, presents a Phase Ib/II trial (NCT04086264) of pivekimab sunirine plus azacitidine and venetoclax in unfit newly diagnosed AML. Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, shares results of the Phase II SAVE study (NCT05360160) exploring an all-oral revumenib, decitabine/cedazuridine, and venetoclax regimen, while Mohammad Maher Abdul-Hay, MD, NYU Langone Health, New York City, NY, discusses early data from the Phase I trial (NCT05143996) of the FLT3 x CD3 bispecific CLN-049 in relapsed or refractory AML. | 18m 17s | ||||||
| 1/22/26 | Managing and preventing differentiation syndrome in APL | In this episode of the VJHemOnc Podcast, we focus on the management and prevention of differentiation syndrome in acute promyelocytic leukemia (APL). We begin with a discussion with Yasmin Abaza, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, on the biological basis of differentiation syndrome, the rationale and mechanism behind steroid prophylaxis, and how the supporting evidence has developed over time. Yannis Valtis, MD, Memorial Sloan Kettering Cancer Center, New York, NY, then briefly comments on emerging therapeutic approaches and the need for prospective trials to better define their role. | 13m 44s | ||||||
| 1/16/26 | Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more | This podcast highlights key non-Hodgkin lymphoma (NHL) updates from ASH 2025 across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. John Burke, MD, Rocky Mountain Cancer Centers, Denver, CO, presents the MorningSun study (NCT05207670) of subcutaneous mosunetuzumab in previously untreated FL, while Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the MITHIC-FL2 trial (NCT05389293) of mosunetuzumab plus zanubrutinib in newly diagnosed FL, followed by results from EPCORE FL-1 (NCT05409066) comparing epcoritamab plus R2 versus R2 alone in relapsed or refractory disease. In DLBCL, Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviews the Phase III OLYMPIA-3 trial (NCT06091865), Jason Westin, MD, MD Anderson Cancer Center, Houston, TX, discusses the Smart Stop study (NCT04978584), and Umberto Vitolo, MD, University of Turin, Italy, with Lorenzo Falchi, covers fixed-duration epcoritamab from the EPCORE DLBCL-3 (NCT05660967) and EPCORE NHL-2 (NCT04663347) trials. Saurabh Dahiya, MD, shares early CAR T-cell data with KITE-753 and KITE-363, Michael Wang, MD, presents Phase I/II sonrotoclax results in MCL (NCT05471843), and Nirav Shah, MD, reviews Phase Ia/b bexobrutideg data in Waldenström’s macroglobulinemia (NCT05131022). | 42m 21s | ||||||
| 1/9/26 | Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more! | This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses redefining functional high-risk myeloma, followed by Nisha Joseph, MD, Winship Cancer Institute, Emory University, Atlanta, GA, who shares results from a Phase II dose-optimization study (NCT04068597) of inobrodib with pomalidomide and dexamethasone. Updates on CAR T-cell therapies are given by Shambavi Richard, MD, Mount Sinai, New York City, NY, Krina Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Samir Parekh, MD, Icahn School of Medicine at Mount Sinai, New York City, NY. Finally, Salomon Manier, MD, PhD, Lille Hospital University, Lille, France, Dickran Kazandjian, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, and Amrita Krishnan, MD, City of Hope, Duarte, CA, discuss T-cell engaging antibodies. | 32m 01s | ||||||
| 12/18/25 | Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more | This podcast features updates in chronic lymphocytic leukemia (CLL) from ASH 2025. Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the Phase III FLAIR study (ISRCTN01844152), followed by Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, who shares further insights. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, shares long-term follow-up results from the GAIA/CLL13 (NCT02950051) trial. Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, shares insights into the Phase III BELLWAVE-010 study (NCT05947851), followed by Jennifer Woyach, MD, The Ohio State University, Columbus, OH, who discusses Phase I results (NCT04775745) of a novel BTK inhibitor rocbrutinib. Finally, Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the CaDAnCe-104 trial (NCT06634589) of the BTK degrader BGB-16673, and Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares two-year follow-up results from the EPCORE CLL-1 trial (NCT04623541) of epcoritamab monotherapy in Richter’s transformation. | 21m 17s | ||||||
| 12/12/25 | Top updates in MDS from ASH 2025: key trial updates and debated topics | In this podcast episode, leading experts share key updates in the management of myelodysplastic syndromes (MDS) from ASH 2025. Amer Zeidan, MBBS, MHS, Yale School of Medicine, New Haven, CT, highlights data from the MAXILUS trial (NCT06045689), new insights from the IMerge study (NCT02598661), and early findings with bexmarilimab in higher-risk MDS (HR-MDS). This is followed by Valeria Santini, MD, University of Florence, Florence, Italy, who discusses long-term outcomes from IMerge and a post-hoc analysis of the COMMANDS trial (NCT03682536). Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, provides perspective on the Phase III VERONA trial (NCT04401748) of azacitidine plus venetoclax in HR-MDS, and Daniel Wiseman, MBChB, PhD, University of Manchester, Manchester, UK, presents results from the Phase II AMMO study (ISRCTN30808508) in MDS-myeloproliferative neoplasm (MPN) overlap syndromes. Finally, Prof. Santini returns to address current debates and controversial topics in the diagnosis and treatment of MDS. | 22m 54s | ||||||
| 11/27/25 | Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more | In this podcast episode, leading experts provide valuable insight into the management of sickle cell disease (SCD). First, Samah Babiker, MBBS, MRCP-UK, FRCPath, Evelina London Children’s Hospital, London, UK, and Payal Desai, MD, Levine Cancer Institute & Wake Forest School of Medicine, Charlotte, NC, discuss the challenges associated with the transition from pediatric to adult care and how to support patients through this period. Following this, Enrico Novelli, MD, MS, University of Pittsburgh, Pittsburgh, PA, shares insight into the management of vaso-occlusive crises, and Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, comments on whether MRI brain assessment should be routinely performed in all patients with SCD. | 18m 49s | ||||||
| 11/20/25 | Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges | This episode of the VJHemOnc podcast focuses on accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP), offering insights into their diagnosis and management from leading experts. First, in an interview with Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, you will hear about the diagnosis, risk stratification, and therapeutic strategies being explored for patients with MPN-AP/BP. Dr Patel will also comment on the role and timing of allogeneic stem cell transplantation (alloSCT) in this patient population. Following this, experts Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Charlotte Brierley, MA, BM BCh, MRCP, DPhil, FRCPath, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clinic of Valencia, Valencia, Spain, will discuss the challenges of managing MPN-AP/BP, highlighting the need for biomarkers to identify patients at risk of aggressive disease progression. | 18m 53s | ||||||
| 11/14/25 | The value and utility of MRD in the management of adults with newly-diagnosed AML | This podcast features experts Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, who debate the value and utility of measurable residual disease (MRD) in the management of adults with newly-diagnosed acute myeloid leukemia (AML). The discussion explores current limitations of MRD assays, the challenges of standardization, and the importance of integrating multiple modalities. This took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC. | 16m 25s | ||||||
| 11/7/25 | Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance | This episode of the VJHemOnc Podcast features discussions from the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC. First, you will hear from Ross Firestone, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Nisha Joseph, MD, Winship Cancer Institute of Emory University, Atlanta, GA, and Ajai Chari, MD, University of California San Francisco, San Francisco, CA, who provide insight into immuno- and targeted therapies in HRMM. This is followed by Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, and Holly Lee, MD, University of Calgary, Calgary, Canada, who discuss resistance to these therapies, highlighting the mechanisms of resistance and potential strategies to overcome them. | 24m 35s | ||||||
| 10/31/25 | Advances in immunotherapy for NHL: updates from iwNHL 2025 | This podcast features discussions from the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL), which took place in Cambridge, MA. The discussions focus on immunotherapy and novel combinations being explored for the treatment of NHL. Featuring experts Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Sameh Gaballa, MD, Moffitt Cancer Center, Tampa, FL, who share insights into bispecific antibodies and other immunotherapeutics in early lines of treatment. This is followed by Laurie Sehn, MD, MPH, BC Cancer Agency, Vancouver, Canada, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, and Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, who delve deeper into antibody-based combinations. | 34m 16s | ||||||
| 10/16/25 | Reviewing recent guideline updates on the risk stratification and treatment of AML | In this episode of the VJHemOnc Podcast, we are joined by Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, and Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, to discuss recent guideline updates on the risk stratification and treatment of acute myeloid leukemia (AML). The experts discuss differences in the World Health Organization (WHO) and International Consensus Classification (ICC) definitions, the recent European Leukemia Network (ELN) updates to risk stratification, incorporating measurable residual disease (MRD) into therapeutic decision-making, and biomarkers or stratification approaches on the horizon. | 28m 54s | ||||||
| 10/16/25 | The management of CLL in resource-limited settings: guideline development and ongoing projects | VJHemOnc recently attended the International Workshop on Chronic Lymphocytic Leukemia (XXI iwCLL 2025) in Krakow, Poland, where there was a session focused on the management of CLL in resource-limited settings. Today's podcast episode highlights discussions from this session. First, you will hear from Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, who discusses the development of resource-restricted recommendations for CLL. This is followed by Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, Andrielle Yost, MPA, The Max Foundation, Seattle, WA, and Catherina Scheepers, The Max Foundation, Gauteng, South Africa, who share ongoing projects by iwCLL and The Max Foundation to improve access to treatment and patient outcomes in low- and middle-income countries. Finally, Brian Koffman, MDCM (retired), CLL Society, Inc., Chula Vista, CA, discusses the six principles for excellence that healthcare professionals and patient advocacy organizations should be aware of when caring for patients with CLL. | 19m 40s | ||||||
| 9/29/25 | The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist | This episode of our Blood Cancer Awareness Month series explores the role of the multi-disciplinary team in caring for patients with blood cancer undergoing CAR T-cell therapy. The discussion features insights from Ty Simpson, BN, MNP, Alfred Health, Melbourne, Australia, who is a CAR-T nurse practitioner, and Frederick Vonberg, MD, University College London Hospitals NHS Foundation Trust, London, UK, who is a neurologist with a primary research interest in the neurotoxic effects of CAR T-cell therapy. This is followed by Angela Halley, MBBS, BSc, MSc, FRCP, Royal Marsden Hospital, London, UK, who is a consultant in palliative medicine with an interest in developing early integrated palliative care in hematology, including patients undergoing CAR-T treatment and stem cell transplant. | 21m 54s | ||||||
| 9/19/25 | Understanding financial and time toxicity in cancer care: advice for community oncologists | Welcome to the next episode in our Blood Cancer Awareness Month series. In this podcast, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses financial and time toxicities in cancer care, explaining how out-of-pocket costs and the time spent receiving treatment impair patients' lives. Dr Banerjee shares insights from his own clinical experience, with a focus on patients with multiple myeloma. | 19m 21s | ||||||
Showing 25 of 200
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
4 placements across 4 markets.
Chart Positions
4 placements across 4 markets.